← Leaderboards
Quanjun Cui
University Of Virginia
$956,244
Attributed
$1,151,407
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $426.4K · FY2012–18$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,151,407 · 3
By mechanism
R21$1,151,407 · 3
Top collaborators
- Dongfeng Pan2 shared
Most similar at University Of Virginia
Same institution · by research overlap
- Xudong Joshua Li$4,493,519
- Owen W. Pornillos$13,511,239
- Barbie K. Ganser-Pornillos$3,771,631
- Jonathan R Lindner$23,863,903
- Dongfeng Pan$195,163
Others in their field
Top investigators on “Inflammatory”
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Edward A Dennis · University Of California, San Diego$72,701,136
- Constance Ann Benson · University Of California, San Diego$65,790,143
- Randall J Bateman · Washington University$62,939,456
- Paul M. Ridker · Brigham And Women'S Hospital$56,179,451
- Keri Hammel · The Emmes Company, Llc$53,700,408
Research focus
InflammatoryBaseBloodPharmaceutical PreparationsMolecularOrthopedicsInjuryComplexFlow CytometryHistologyIn VitroIn VivoNovel TherapeuticsOperative Surgical ProceduresBoneBone MarrowCellsClinical TrialsAffectEarly DiagnosisDiagnostic Radiologic ExaminationImmuneInnovationPlay
Grant awards (6)
Inhibition of MSC1 stem cells and T cells to endorse bone healing$213,180
R21 · FY2018 · AR · contact PI
A novel inflammation targeting Tc-99m probe for osteoarthritis imaging$213,180
R21 · FY2018 · AR · contact PI
Inhibition of MSC1 stem cells and T cells to endorse bone healing$177,146
R21 · FY2017 · AR · contact PI
A novel inflammation targeting Tc-99m probe for osteoarthritis imaging$177,146
R21 · FY2017 · AR · contact PI
Treatment of glucocorticoid-induced osteonecrosis with nano-fullerenes$197,505
R21 · FY2013 · AR · contact PI
Treatment of glucocorticoid-induced osteonecrosis with nano-fullerenes$173,250
R21 · FY2012 · AR · contact PI